Reply: Evaluation of the Inclisiran Safety in High-Risk Populations

J Am Coll Cardiol. 2024 Apr 2;83(13):e129. doi: 10.1016/j.jacc.2024.01.032. Epub 2024 Mar 25.

Authors

R Scott Wright¹, Lawrence A Leiter², Anastasia Lesogor³, Kausik K Ray⁴

Affiliations

¹ Mayo Clinic, Rochester, Minnesota, USA. Electronic address: [email protected].
² Li Ka Shing Knowledge Institute, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
³ Novartis Pharma AG, Basel, Switzerland.
⁴ Imperial Centre for Cardiovascular Disease Prevention, Imperial College London, London, United Kingdom.

PMID: 38538207
DOI: 10.1016/j.jacc.2024.01.032

No abstract available

Publication types

Letter

MeSH terms

Anticholesteremic Agents*
Humans
Hypercholesterolemia*
Proprotein Convertase 9
RNA, Small Interfering

Substances

ALN-PCS
Anticholesteremic Agents
RNA, Small Interfering
Proprotein Convertase 9